Rajiv Radhakrishnan, MBBS, MD, FAPA
Addiction Medicine, Psychiatry
Biography
Rajiv Radhakrishnan, MD, is a psychiatrist who specializes in addiction medicine. He provides care for individuals with substance use disorders, offering strategies to manage cravings and withdrawal symptoms.
As an associate professor of psychiatry at Yale School of Medicine, Dr. Radhakrishnan investigates how certain substances can influence psychotic disorders like schizophrenia. He focuses on improving treatment approaches for people experiencing substance-induced psychosis.
Dr. Radhakrishnan completed his medical training at St. John’s Medical College and pursued further psychiatric training at Yale School of Medicine. He has been honored by the Society for Nuclear Medicine and Molecular Imaging, the American Society of Clinical Psychopharmacology, and the Society of Biological Psychiatry.
Titles
- Associate Professor of Psychiatry
- Associate Professor, Radiology and Biomedical Imaging
- Co-Medical Director, Yale PET Center
- Affiliated Faculty, Yale Institute for Global Health
Education & Training
- MHSYale University (2021)
- MDSt. John's Medical College (2008)
- MBBSSt John's Medical College, Medicine (2003)
Languages Spoken
- English
- हिन्दी (Hindi)
- ಕನ್ನಡ (Kannada)
Additional Information
Honors & Recognitions
- NIH Early Career Reviewer: NIH CSR (2020)
- 2020 CPDD Travel Award for Early Career Investigators: College on Problems of Drug Dependence (CPDD) (2020)
- ISCTM 2020 New Investigator Award: International Society for CNS Clinical Trials Methodology (ISCTM) (2019)
- Alavi-Mandell Award: Society for Nuclear Medicine and Molecular Imaging (SNMMI) (2019)
- American College of Neuropsychopharmacology Travel Award 2018: (2018)
- Seymour Lustman Resident Research Award 2018: Yale Department of Psychiatry (2018)
- YCCI Scholar Award (2018 - 2020): Institutional K award (KL-2) (2018)
- American Society of Clinical Psychopharmacology (ASCP) New Investigator Award: American Society of Clinical Psychopharmacology (ASCP) (2017)
- Dana Foundation: David Mahoney Neuroimaging Program Award 2016: Dana Foundation (2016)
- Laughlin Family Foundation Outstanding Psychiatric Resident Award 2016: (2016)
Board Certifications
- AB of Preventive Medicine, Addiction Medicine (Preventive Medicine) (2020)
Professional Service
- American Psychiatric Association (2021 - Present): Fellow
- American Society of Clinical Psychopharmacology (ASCP) (2019 - Present): ASCP Technology Task Force
- Journal of Dual Diagnosis (2019 - Present): Associate Editor
- Schizophrenia International Research Society (SIRS) (2019 - Present): Committee Member
- Medical Research Council (MRC), UK (2019 - Present): Ad-hoc reviewer
- American Society of Clinical Psychopharmacology (ASCP) (2017 - Present): Committee Member
- Yale University Human Investigation Committee (HIC) (2016 - Present): Member
- American Journal of Psychiatry-Residents' Journal (2015 - 2016): Editor-in-Chief (2015-16)
- American Journal of Psychiatry-Residents' Journal (2014 - 2015): Senior-Deputy Editor
Publications
- Syed S, Singh J, Elkholy H, Palavra I, Tomicevic M, Eric A, da Costa M, Guloksuz S, Radhakrishnan R. International perspectives on physician knowledge, attitudes, and practices related to medical cannabis. Frontiers In Public Health 2025, 13: 1463871. PMID: 40051509, PMCID: PMC11882600, DOI: 10.3389/fpubh.2025.1463871.
- Menon J, Kantipudi S, Mani A, Radhakrishnan R. Cognitive functioning and functional ability in women with schizophrenia and homelessness. Schizophrenia Research Cognition 2024, 39: 100338. PMID: 39610698, PMCID: PMC11603006, DOI: 10.1016/j.scog.2024.100338.
- Christian N, Zhou X, Radhakrishnan R. Effects of Buprenorphine, Methadone, and Substance Use on COVID-19 Morbidity and Mortality. Journal Of Addiction Medicine 2024, 19: 223-226. PMID: 39475125, DOI: 10.1097/adm.0000000000001386.
- Matuskey D, Yang Y, Naganawa M, Koohsari S, Toyonaga T, Gravel P, Pittman B, Torres K, Pisani L, Finn C, Cramer-Benjamin S, Herman N, Rosenthal L, Franke C, Walicki B, Esterlis I, Skosnik P, Radhakrishnan R, Wolf J, Nabulsi N, Ropchan J, Huang Y, Carson R, Naples A, McPartland J. 11C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults. Molecular Psychiatry 2024, 30: 1610-1616. PMID: 39367053, DOI: 10.1038/s41380-024-02776-2.
- Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.
- Oliva H, Prudente T, Nunes E, Cosgrove K, Radhakrishnan R, Potenza M, Angarita G. Substance use and spine density: a systematic review and meta-analysis of preclinical studies. Molecular Psychiatry 2024, 29: 2873-2885. PMID: 38561468, PMCID: PMC11894807, DOI: 10.1038/s41380-024-02519-3.
- Radhakrishnan R. In Vivo Synaptic Density in Early Schizophrenia: Are There No Differences or Are They Too Small to Detect? Biological Psychiatry 2024, 95: 605-607. PMID: 38479976, DOI: 10.1016/j.biopsych.2024.01.016.
- Hird R, Radhakrishnan R, Tsai J. A systematic review of approaches to improve medication adherence in homeless adults with psychiatric disorders. Frontiers In Psychiatry 2024, 14: 1339801. PMID: 38260790, PMCID: PMC10800888, DOI: 10.3389/fpsyt.2023.1339801.
- Orhii P, Radhakrishnan R, Selvaraj S. PET Biomarkers in Psychiatry. 2023, 81-104. DOI: 10.1007/978-3-031-43356-6_6.
- Toyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
- Christian N, Zhou X, Radhakrishnan R. Substance Use Disorder and Health Outcomes in COVID-19—The Need for a Better Research Method to Determine Substance Use Exposure. JAMA Psychiatry 2023, 80: 968-968. PMID: 37405794, DOI: 10.1001/jamapsychiatry.2023.2113.
- Jauhar S, Arnone D, Baldwin D, Bloomfield M, Browning M, Cleare A, Corlett P, Deakin J, Erritzoe D, Fu C, Fusar-Poli P, Goodwin G, Hayes J, Howard R, Howes O, Juruena M, Lam R, Lawrie S, McAllister-Williams H, Marwaha S, Matuskey D, McCutcheon R, Nutt D, Pariante C, Pillinger T, Radhakrishnan R, Rucker J, Selvaraj S, Stokes P, Upthegrove R, Yalin N, Yatham L, Young A, Zahn R, Cowen P. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Molecular Psychiatry 2023, 28: 3149-3152. PMID: 37322065, PMCID: PMC10618084, DOI: 10.1038/s41380-023-02095-y.
- Syed S, Singh J, Elkholy H, Rojnić Palavra I, Tomicevic M, Eric A, Pinto da Costa M, Guloksuz S, Radhakrishnan R. Impact of personal beliefs about medical cannabis on physician recommendation practices: Results of an international survey. Asian Journal Of Psychiatry 2023, 85: 103634. PMID: 37257363, DOI: 10.1016/j.ajp.2023.103634.
- Kamal S, Jha M, Radhakrishnan R. Role of Psychedelics in Treatment-Resistant Depression. Psychiatric Clinics Of North America 2023, 46: 291-305. PMID: 37149346, DOI: 10.1016/j.psc.2023.02.004.
- Radhakrishnan R, Worhunsky PD, Zheng MQ, Najafzadeh S, Gallezot JD, Planeta B, Henry S, Nabulsi N, Ranganathan M, Skosnik PD, Pittman B, Cyril D'Souza D, Carson RE, Huang Y, Potenza MN, Matuskey D. Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PET. NeuroImage 2022, 264: 119674. PMID: 36243269, DOI: 10.1016/j.neuroimage.2022.119674.
- Radhakrishnan R, Pries LK, Erzin G, Have M, de Graaf R, van Dorsselaer S, Gunther N, Bak M, Rutten BPF, van Os J, Guloksuz S. Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis. Psychological Medicine 2022, 53: 5551-5557. PMID: 36093677, PMCID: PMC10482707, DOI: 10.1017/s0033291722002756.
- Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.
- Ramakrishnan D, Sureshanand S, Pittman B, Radhakrishnan R. Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study. The Journal Of Clinical Psychiatry 2022, 83 PMID: 36044600, DOI: 10.4088/jcp.21m14332.
- Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.
- Radhakrishnan R, Guloksuz S, D'Souza DC, van Os J. Editorial: Gone to Pot: Examining the Association Between Cannabis Use and Medical/Psychiatric Disorders. Frontiers In Psychiatry 2022, 13: 837757. PMID: 35211046, PMCID: PMC8861305, DOI: 10.3389/fpsyt.2022.837757.
- Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.
- Radhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, Hillmer AT, Esterlis I, Huang Y, Nabulsi N, Carson RE, D’Souza D. In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular Psychiatry 2021, 26: 7690-7698. PMID: 34135473, DOI: 10.1038/s41380-021-01184-0.
- Finnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.
- Radhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research Neuroimaging 2019, 295: 111007. PMID: 31760336, DOI: 10.1016/j.pscychresns.2019.111007.
- Radhakrishnan R. 20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME. Schizophrenia Bulletin 2019, 45: s121-s121. PMCID: PMC6455407, DOI: 10.1093/schbul/sbz022.079.
- D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry 2018, 6: 35-45. PMID: 30528676, DOI: 10.1016/s2215-0366(18)30427-9.
- Radhakrishnan R, Guloksuz S, Have M, de Graaf R, van Dorsselaer S, Gunther N, Rauschenberg C, Reininghaus U, Pries LK, Bak M, van Os J. Interaction between environmental and familial affective risk impacts psychosis admixture in states of affective dysregulation. Psychological Medicine 2018, 49: 1879-1889. PMID: 30284529, DOI: 10.1017/s0033291718002635.
- Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC. GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC. Neuropsychopharmacology 2015, 40: 2047-2056. PMID: 25728472, PMCID: PMC4839528, DOI: 10.1038/npp.2015.58.
- Radhakrishnan R, Addy P, Sewell R, Skosnik P, Ranganathan M, D’Souza D. Chapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis. 2014, 423-474. DOI: 10.1016/b978-0-12-418679-8.00014-9.
- Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D’Souza D. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology 2012, 226: 401-413. PMID: 23179965, PMCID: PMC3581701, DOI: 10.1007/s00213-012-2915-6.
- D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. Neuropsychopharmacology 2012, 38: 492-503. PMID: 23093223, PMCID: PMC3547200, DOI: 10.1038/npp.2012.208.
Departments and Programs
Biography
Rajiv Radhakrishnan, MD, is a psychiatrist who specializes in addiction medicine. He provides care for individuals with substance use disorders, offering strategies to manage cravings and withdrawal symptoms.
As an associate professor of psychiatry at Yale School of Medicine, Dr. Radhakrishnan investigates how certain substances can influence psychotic disorders like schizophrenia. He focuses on improving treatment approaches for people experiencing substance-induced psychosis.
Dr. Radhakrishnan completed his medical training at St. John’s Medical College and pursued further psychiatric training at Yale School of Medicine. He has been honored by the Society for Nuclear Medicine and Molecular Imaging, the American Society of Clinical Psychopharmacology, and the Society of Biological Psychiatry.
Titles
- Associate Professor of Psychiatry
- Associate Professor, Radiology and Biomedical Imaging
- Co-Medical Director, Yale PET Center
- Affiliated Faculty, Yale Institute for Global Health
Education & Training
- MHSYale University (2021)
- MDSt. John's Medical College (2008)
- MBBSSt John's Medical College, Medicine (2003)
Languages Spoken
- English
- हिन्दी (Hindi)
- ಕನ್ನಡ (Kannada)
Additional Information
Honors & Recognitions
- NIH Early Career Reviewer: NIH CSR (2020)
- 2020 CPDD Travel Award for Early Career Investigators: College on Problems of Drug Dependence (CPDD) (2020)
- ISCTM 2020 New Investigator Award: International Society for CNS Clinical Trials Methodology (ISCTM) (2019)
- Alavi-Mandell Award: Society for Nuclear Medicine and Molecular Imaging (SNMMI) (2019)
- American College of Neuropsychopharmacology Travel Award 2018: (2018)
- Seymour Lustman Resident Research Award 2018: Yale Department of Psychiatry (2018)
- YCCI Scholar Award (2018 - 2020): Institutional K award (KL-2) (2018)
- American Society of Clinical Psychopharmacology (ASCP) New Investigator Award: American Society of Clinical Psychopharmacology (ASCP) (2017)
- Dana Foundation: David Mahoney Neuroimaging Program Award 2016: Dana Foundation (2016)
- Laughlin Family Foundation Outstanding Psychiatric Resident Award 2016: (2016)
Board Certifications
- AB of Preventive Medicine, Addiction Medicine (Preventive Medicine) (2020)
Professional Service
- American Psychiatric Association (2021 - Present): Fellow
- American Society of Clinical Psychopharmacology (ASCP) (2019 - Present): ASCP Technology Task Force
- Journal of Dual Diagnosis (2019 - Present): Associate Editor
- Schizophrenia International Research Society (SIRS) (2019 - Present): Committee Member
- Medical Research Council (MRC), UK (2019 - Present): Ad-hoc reviewer
- American Society of Clinical Psychopharmacology (ASCP) (2017 - Present): Committee Member
- Yale University Human Investigation Committee (HIC) (2016 - Present): Member
- American Journal of Psychiatry-Residents' Journal (2015 - 2016): Editor-in-Chief (2015-16)
- American Journal of Psychiatry-Residents' Journal (2014 - 2015): Senior-Deputy Editor
Publications
- Syed S, Singh J, Elkholy H, Palavra I, Tomicevic M, Eric A, da Costa M, Guloksuz S, Radhakrishnan R. International perspectives on physician knowledge, attitudes, and practices related to medical cannabis. Frontiers In Public Health 2025, 13: 1463871. PMID: 40051509, PMCID: PMC11882600, DOI: 10.3389/fpubh.2025.1463871.
- Menon J, Kantipudi S, Mani A, Radhakrishnan R. Cognitive functioning and functional ability in women with schizophrenia and homelessness. Schizophrenia Research Cognition 2024, 39: 100338. PMID: 39610698, PMCID: PMC11603006, DOI: 10.1016/j.scog.2024.100338.
- Christian N, Zhou X, Radhakrishnan R. Effects of Buprenorphine, Methadone, and Substance Use on COVID-19 Morbidity and Mortality. Journal Of Addiction Medicine 2024, 19: 223-226. PMID: 39475125, DOI: 10.1097/adm.0000000000001386.
- Matuskey D, Yang Y, Naganawa M, Koohsari S, Toyonaga T, Gravel P, Pittman B, Torres K, Pisani L, Finn C, Cramer-Benjamin S, Herman N, Rosenthal L, Franke C, Walicki B, Esterlis I, Skosnik P, Radhakrishnan R, Wolf J, Nabulsi N, Ropchan J, Huang Y, Carson R, Naples A, McPartland J. 11C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults. Molecular Psychiatry 2024, 30: 1610-1616. PMID: 39367053, DOI: 10.1038/s41380-024-02776-2.
- Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.
- Oliva H, Prudente T, Nunes E, Cosgrove K, Radhakrishnan R, Potenza M, Angarita G. Substance use and spine density: a systematic review and meta-analysis of preclinical studies. Molecular Psychiatry 2024, 29: 2873-2885. PMID: 38561468, PMCID: PMC11894807, DOI: 10.1038/s41380-024-02519-3.
- Radhakrishnan R. In Vivo Synaptic Density in Early Schizophrenia: Are There No Differences or Are They Too Small to Detect? Biological Psychiatry 2024, 95: 605-607. PMID: 38479976, DOI: 10.1016/j.biopsych.2024.01.016.
- Hird R, Radhakrishnan R, Tsai J. A systematic review of approaches to improve medication adherence in homeless adults with psychiatric disorders. Frontiers In Psychiatry 2024, 14: 1339801. PMID: 38260790, PMCID: PMC10800888, DOI: 10.3389/fpsyt.2023.1339801.
- Orhii P, Radhakrishnan R, Selvaraj S. PET Biomarkers in Psychiatry. 2023, 81-104. DOI: 10.1007/978-3-031-43356-6_6.
- Toyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
- Christian N, Zhou X, Radhakrishnan R. Substance Use Disorder and Health Outcomes in COVID-19—The Need for a Better Research Method to Determine Substance Use Exposure. JAMA Psychiatry 2023, 80: 968-968. PMID: 37405794, DOI: 10.1001/jamapsychiatry.2023.2113.
- Jauhar S, Arnone D, Baldwin D, Bloomfield M, Browning M, Cleare A, Corlett P, Deakin J, Erritzoe D, Fu C, Fusar-Poli P, Goodwin G, Hayes J, Howard R, Howes O, Juruena M, Lam R, Lawrie S, McAllister-Williams H, Marwaha S, Matuskey D, McCutcheon R, Nutt D, Pariante C, Pillinger T, Radhakrishnan R, Rucker J, Selvaraj S, Stokes P, Upthegrove R, Yalin N, Yatham L, Young A, Zahn R, Cowen P. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Molecular Psychiatry 2023, 28: 3149-3152. PMID: 37322065, PMCID: PMC10618084, DOI: 10.1038/s41380-023-02095-y.
- Syed S, Singh J, Elkholy H, Rojnić Palavra I, Tomicevic M, Eric A, Pinto da Costa M, Guloksuz S, Radhakrishnan R. Impact of personal beliefs about medical cannabis on physician recommendation practices: Results of an international survey. Asian Journal Of Psychiatry 2023, 85: 103634. PMID: 37257363, DOI: 10.1016/j.ajp.2023.103634.
- Kamal S, Jha M, Radhakrishnan R. Role of Psychedelics in Treatment-Resistant Depression. Psychiatric Clinics Of North America 2023, 46: 291-305. PMID: 37149346, DOI: 10.1016/j.psc.2023.02.004.
- Radhakrishnan R, Worhunsky PD, Zheng MQ, Najafzadeh S, Gallezot JD, Planeta B, Henry S, Nabulsi N, Ranganathan M, Skosnik PD, Pittman B, Cyril D'Souza D, Carson RE, Huang Y, Potenza MN, Matuskey D. Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PET. NeuroImage 2022, 264: 119674. PMID: 36243269, DOI: 10.1016/j.neuroimage.2022.119674.
- Radhakrishnan R, Pries LK, Erzin G, Have M, de Graaf R, van Dorsselaer S, Gunther N, Bak M, Rutten BPF, van Os J, Guloksuz S. Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis. Psychological Medicine 2022, 53: 5551-5557. PMID: 36093677, PMCID: PMC10482707, DOI: 10.1017/s0033291722002756.
- Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.
- Ramakrishnan D, Sureshanand S, Pittman B, Radhakrishnan R. Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study. The Journal Of Clinical Psychiatry 2022, 83 PMID: 36044600, DOI: 10.4088/jcp.21m14332.
- Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.
- Radhakrishnan R, Guloksuz S, D'Souza DC, van Os J. Editorial: Gone to Pot: Examining the Association Between Cannabis Use and Medical/Psychiatric Disorders. Frontiers In Psychiatry 2022, 13: 837757. PMID: 35211046, PMCID: PMC8861305, DOI: 10.3389/fpsyt.2022.837757.
- Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.
- Radhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, Hillmer AT, Esterlis I, Huang Y, Nabulsi N, Carson RE, D’Souza D. In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular Psychiatry 2021, 26: 7690-7698. PMID: 34135473, DOI: 10.1038/s41380-021-01184-0.
- Finnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.
- Radhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research Neuroimaging 2019, 295: 111007. PMID: 31760336, DOI: 10.1016/j.pscychresns.2019.111007.
- Radhakrishnan R. 20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME. Schizophrenia Bulletin 2019, 45: s121-s121. PMCID: PMC6455407, DOI: 10.1093/schbul/sbz022.079.
- D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry 2018, 6: 35-45. PMID: 30528676, DOI: 10.1016/s2215-0366(18)30427-9.
- Radhakrishnan R, Guloksuz S, Have M, de Graaf R, van Dorsselaer S, Gunther N, Rauschenberg C, Reininghaus U, Pries LK, Bak M, van Os J. Interaction between environmental and familial affective risk impacts psychosis admixture in states of affective dysregulation. Psychological Medicine 2018, 49: 1879-1889. PMID: 30284529, DOI: 10.1017/s0033291718002635.
- Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC. GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC. Neuropsychopharmacology 2015, 40: 2047-2056. PMID: 25728472, PMCID: PMC4839528, DOI: 10.1038/npp.2015.58.
- Radhakrishnan R, Addy P, Sewell R, Skosnik P, Ranganathan M, D’Souza D. Chapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis. 2014, 423-474. DOI: 10.1016/b978-0-12-418679-8.00014-9.
- Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D’Souza D. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology 2012, 226: 401-413. PMID: 23179965, PMCID: PMC3581701, DOI: 10.1007/s00213-012-2915-6.
- D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. Neuropsychopharmacology 2012, 38: 492-503. PMID: 23093223, PMCID: PMC3547200, DOI: 10.1038/npp.2012.208.
Departments and Programs